Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 1/20 | 0.50 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | TDP2 | O95551 | 1/20 | 0.49 |
| ▸ | ASIC3 | Q9UHC3 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | CD44 | P16070 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29543554 | 1.00 | TYRO3 (0.50) | TYRO3NTRK2CLK4DYRK1BTDP2 | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL4892220 | 0.85 | PNMT (0.66) | ASIC3PNMTCD44MAOBCD274 | |
| SCHEMBL6347388 | 0.84 | ASIC3 (0.65) | ASIC3PARP10PARP11PNMTCD44 | |
| SCHEMBL30593253 | 0.84 | PNMT (0.59) | ASIC3PARP10PARP11PNMTCD44 | |
| SCHEMBL4663734 | 0.84 | PNMT (0.59) | ASIC3PARP10PARP11PNMTCD44 | |
| SCHEMBL29543449 | 0.81 | ASIC3 (0.50) | TDP2ASIC3PNMTALDH1A1 | |
| SCHEMBL29543416 | 0.81 | ASIC3 (0.56) | NTRK2TDP2ASIC3ALOX5PNMT | |
| SCHEMBL22638762 | 0.81 | CYP2D6 (0.49) | TDP2ASIC3HTR1AHTR7 | |
| SCHEMBL29386484 | 0.81 | CYP2D6 (0.49) | TDP2ASIC3HTR1AHTR7 | |
| SCHEMBL30948932 | 0.79 | PDE3B (0.50) | ASIC3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118515600-A | Isoindoline compound and medical application thereof | 中国科学院上海药物研究所 | 2024-08-20 | — | — | CN | disclosed |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
| EP-3800186-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | Mission Therapeutics Limited (GB) | 2021-04-07 | — | — | EP | disclosed |
| US-20200231542-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2020-07-23 | — | — | US | disclosed |
| US-10669234-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-02 | — | — | US | disclosed |
| US-10662159-B2 | ABHD6 and dual ABHD6/MGL inhibitors and their uses | MAKSCIENTIFIC, LLC (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3322702-B1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LTD (GB) | 2019-11-20 | — | — | EP | disclosed |
| US-20190152917-A1 | ABHD6 AND DUAL ABHD6/MGL INHIBITORS AND THEIR USES | MAKSCIENTIFIC, LLC | 2019-05-23 | — | — | US | disclosed |
| US-20180194724-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-5726197-A | ADRENORECEPTORS AND ADMINISTERING | SYNTEX (U.S.A.) INC. (US) | 1998-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662159-B2 | ABHD6 and dual ABHD6/MGL inhibitors and their uses | ABHD6, FAAH, FAAH2 | TYRO3 4534/4885NTRK2 2814/4885CLK4 1352/4885 |
| US-10669234-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | USP30, USP39, UCHL1 | TYRO3 3944/4885NTRK2 4458/4885CLK4 2115/4885 |
| US-20180194724-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | USP30, USP39, UCHL1 | TYRO3 3944/4885NTRK2 4458/4885CLK4 2115/4885 |
| US-20190152917-A1 | ABHD6 AND DUAL ABHD6/MGL INHIBITORS AND THEIR USES | ABHD6, FAAH, FAAH2 | TYRO3 4534/4885NTRK2 2814/4885CLK4 1352/4885 |
| US-20200231542-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | USP30, USP39, UCHL1 | TYRO3 3944/4885NTRK2 4458/4885CLK4 2115/4885 |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | USP30, USP39, UCHL1 | TYRO3 3944/4885NTRK2 4458/4885CLK4 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.